Accelerate Diagnostics Stock Z Score
AXDX Stock | USD 0.95 0.06 6.74% |
Accelerate | Z Score |
Accelerate Diagnostics Company Z Score Analysis
Accelerate Diagnostics' Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
| |||||||
| |||||||
| |||||||
| |||||||
|
Accelerate Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for Accelerate Diagnostics is extremely important. It helps to project a fair market value of Accelerate Stock properly, considering its historical fundamentals such as Z Score. Since Accelerate Diagnostics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Accelerate Diagnostics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Accelerate Diagnostics' interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
Competition |
In accordance with the company's disclosures, Accelerate Diagnostics has a Z Score of 0.0. This is 100.0% lower than that of the Life Sciences Tools & Services sector and 100.0% lower than that of the Health Care industry. The z score for all United States stocks is 100.0% higher than that of the company.
Accelerate Diagnostics Institutional Holders
Institutional Holdings refers to the ownership stake in Accelerate Diagnostics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Accelerate Diagnostics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Accelerate Diagnostics' value.Shares | State Street Corporation | 2023-12-31 | 23.5 K | Ironwood Wealth Management, Llc | 2024-03-31 | 19.8 K | Sonora Investment Management Group, Llc | 2023-12-31 | 18 K | Tudor Investment Corp Et Al | 2023-12-31 | 14.1 K | Millennium Management Llc | 2023-12-31 | 13.9 K | Tejara Capital Ltd | 2023-12-31 | 13.6 K | Thompson Investment Management Llc | 2023-12-31 | 10.4 K | Ubs Group Ag | 2023-12-31 | 10 K | Royal Bank Of Canada | 2023-12-31 | 9.3 K | Hovey Youngman Associates Inc | 2024-03-31 | 1.4 M | Vanguard Group Inc | 2023-12-31 | 306.6 K |
Accelerate Fundamentals
Return On Asset | -0.7 | ||||
Operating Margin | (3.54) % | ||||
Current Valuation | 44.61 M | ||||
Shares Outstanding | 21.66 M | ||||
Shares Owned By Insiders | 37.11 % | ||||
Shares Owned By Institutions | 12.77 % | ||||
Number Of Shares Shorted | 292.63 K | ||||
Price To Earning | (15.18) X | ||||
Price To Sales | 1.60 X | ||||
Revenue | 12.06 M | ||||
Gross Profit | 3.3 M | ||||
EBITDA | (50.77 M) | ||||
Net Income | (61.62 M) | ||||
Cash And Equivalents | 36.77 M | ||||
Cash Per Share | 0.45 X | ||||
Total Debt | 39.22 M | ||||
Debt To Equity | 2.76 % | ||||
Current Ratio | 4.48 X | ||||
Book Value Per Share | (1.36) X | ||||
Cash Flow From Operations | (40.2 M) | ||||
Short Ratio | 4.41 X | ||||
Earnings Per Share | (4.94) X | ||||
Price To Earnings To Growth | (0.55) X | ||||
Target Price | 1.5 | ||||
Number Of Employees | 134 | ||||
Beta | 0.53 | ||||
Market Capitalization | 19.22 M | ||||
Total Asset | 31.37 M | ||||
Retained Earnings | (668.86 M) | ||||
Working Capital | 12.43 M | ||||
Current Asset | 91.68 M | ||||
Current Liabilities | 4.45 M | ||||
Net Asset | 31.37 M |
About Accelerate Diagnostics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Accelerate Diagnostics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Accelerate Diagnostics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Accelerate Diagnostics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Accelerate Diagnostics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Accelerate Diagnostics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Accelerate Diagnostics will appreciate offsetting losses from the drop in the long position's value.Moving against Accelerate Stock
0.82 | OPT | Opthea | PairCorr |
0.72 | LLY | Eli Lilly Earnings Call This Week | PairCorr |
0.65 | ICLR | ICON PLC Earnings Call This Week | PairCorr |
0.61 | PBH | Prestige Brand Holdings Financial Report 2nd of May 2024 | PairCorr |
0.6 | MRK | Merck Company Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Accelerate Diagnostics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Accelerate Diagnostics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Accelerate Diagnostics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Accelerate Diagnostics to buy it.
The correlation of Accelerate Diagnostics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Accelerate Diagnostics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Accelerate Diagnostics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Accelerate Diagnostics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Accelerate Diagnostics Piotroski F Score and Accelerate Diagnostics Valuation analysis. For more information on how to buy Accelerate Stock please use our How to Invest in Accelerate Diagnostics guide.Note that the Accelerate Diagnostics information on this page should be used as a complementary analysis to other Accelerate Diagnostics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Complementary Tools for Accelerate Stock analysis
When running Accelerate Diagnostics' price analysis, check to measure Accelerate Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Accelerate Diagnostics is operating at the current time. Most of Accelerate Diagnostics' value examination focuses on studying past and present price action to predict the probability of Accelerate Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Accelerate Diagnostics' price. Additionally, you may evaluate how the addition of Accelerate Diagnostics to your portfolios can decrease your overall portfolio volatility.
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |
Is Accelerate Diagnostics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Accelerate Diagnostics. If investors know Accelerate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Accelerate Diagnostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.94) | Revenue Per Share 0.966 | Quarterly Revenue Growth 0.019 | Return On Assets (0.70) |
The market value of Accelerate Diagnostics is measured differently than its book value, which is the value of Accelerate that is recorded on the company's balance sheet. Investors also form their own opinion of Accelerate Diagnostics' value that differs from its market value or its book value, called intrinsic value, which is Accelerate Diagnostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Accelerate Diagnostics' market value can be influenced by many factors that don't directly affect Accelerate Diagnostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Accelerate Diagnostics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Accelerate Diagnostics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Accelerate Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.